Published in Vaccine Weekly, January 8th, 2003
Kenneth T. Mountzouros and colleagues working at Wyeth Research in West Henrietta, New York, assessed the efficacy of a glycoconjugate N. meningitidis vaccine.
Antibodies produced after immunization with this vaccine candidate protected rats against bacterial meningitis, Mountzouros and coauthors found.
The researchers measured anti-N. meningitidis serogroup C capsular polysaccharide (PS) immunoglobulin G (IgG) levels in pooled...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2003-01-08)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.